Disease Domain | Count |
---|---|
Infectious Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Vaccine | 2 |
CIK therapy | 1 |
Target- |
Mechanism Immunologic cytotoxicity [+1] |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Immunostimulants |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication- |
Drug Highest Phase- |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Immunostimulants |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication- |
Drug Highest Phase- |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date26 Mar 2021 |
Sponsor / Collaborator PATH Corp. [+4] |
Start Date03 Apr 2020 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
K-NK-ID101 | COVID-19 More | Phase 2 Clinical |
Novel Oral Polio Vaccine Type 3 (nOPV3)(Viroclinics Biosciences) | Poliomyelitis More | Phase 1 |
Novel Oral Polio Vaccine Type 1 (nOPV1)(Viroclinics Biosciences) | Poliomyelitis More | Phase 1 |